Press release - 07/02/2025 Spliceosome: How cells avoid errors when manufacturing mRNA The spliceosome, ensures that the genetic information from the genome, after being transcribed into mRNA precursors, is correctly assembled into mature mRNA. Splicing is a basic requirement for producing proteins. Researchers at the Heidelberg University Biochemistry Center (BZH) have succeeded for the first time in depicting a faultily “blocked” spliceosome at high resolution and reconstructing how it is recognized and eliminated in the cell. https://www.gesundheitsindustrie-bw.de/en/article/press-release/spliceosome-how-cells-avoid-errors-when-manufacturing-mrna
Press release - 07/02/2025 Multiple myeloma: When cancer cells break out of the bone marrow, a dangerous diversity arises A research team from the Heidelberg Medical Faculty, the German Cancer Research Center, the Berlin Institute of Health at Charité (BIH) and the Max Delbrück Center has discovered new details about the spread of the incurable bone marrow cancer multiple myeloma in the body: When the cancer cells break out of the bone and multiply outside the bone marrow, a wide variety of tumor cells arise, accompanied by a significantly altered immune response. https://www.gesundheitsindustrie-bw.de/en/article/press-release/multiple-myeloma-when-cancer-cells-break-out-bone-marrow-dangerous-diversity-arises
Press release - 20/01/2025 New approach to fighting cancer: energy trap for tumor cells Glycolysis is an important sugar degradation pathway that cancer cells in particular depend on. Scientists at the German Cancer Research Center (DKFZ) have now shown that liver cancer cells in mice and humans depend on a key enzyme of glycolysis, Aldolase A. When it is switched off, glycolysis reverses from an energy-producing to an energy-consuming process. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-fighting-cancer-energy-trap-tumor-cells
Press release - 20/01/2025 PAMSARC: New study at the NCT Heidelberg links research and clinical action Young patients suffering from two aggressive sarcoma types can now participate in the innovative PAMSARC therapy study at the NCT Heidelberg. The study uses molecular biological methods and tests the extent to which a new drug can improve the poor prognosis for these tumours.https://www.gesundheitsindustrie-bw.de/en/article/press-release/pamsarc-new-study-nct-heidelberg-links-research-and-clinical-action
Press release - 14/01/2025 Epigenetics ensures placenta functioning If the development of blood vessels in the placenta is impaired, fetal growth retardation may result. Scientists from the German Cancer Research Center (DKFZ) and the Mannheim Medical Faculty of Heidelberg University discovered that the correct development of functioning blood vessels in the mouse placenta is controlled epigenetically: One of the enzymes that modify gene activity using methyl groups is responsible. https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetics-ensures-placenta-functioning
Press release - 07/01/2025 Revolutionising cancer therapy with protein design A new family of protein-based antagonists has been created by researchers that efficiently block the granulocyte-colony stimulating factor receptor (G-CSFR), which is essential for the development of leukaemia and other inflammatory illnesses. This groundbreaking work paves the way for targeted therapies that could revolutionise treatment options for patients suffering from these conditions.https://www.gesundheitsindustrie-bw.de/en/article/press-release/revolutionising-cancer-therapy-protein-design
Press release - 07/01/2025 Researchers have a better understanding of how our cells dispose of waste while developing ways to control it A research team from Freiburg and Frankfurt has discovered how cells recognise and internally break down waste. The results are relevant for the development of therapies for diseases such as Alzheimer’s.https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-have-better-understanding-how-our-cells-dispose-waste-while-developing-ways-control-it
Press release - 03/01/2025 New approaches against metastatic breast cancer: mini-tumors from circulating cancer cells Tumor cells circulating in the blood are the "germ cells" of breast cancer metastases. They are rare and could not be propagated in the culture dish until now, which made research into therapy resistance difficult. A team from the DKFZ, the Heidelberg Stem Cell Institute HI-STEM and the NCT Heidelberg has now succeeded for the first time in cultivating stable tumor organoids directly from blood samples of breast cancer patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approaches-against-metastatic-breast-cancer-mini-tumors-circulating-cancer-cells
Press release - 13/12/2024 Schizophrenia: NMI observes processes in nerve cells Up to now, schizophrenia has mainly been treated symptomatically, as little is known about the exact underlying processes. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen have succeeded in gaining a better understanding of the driving mechanisms of the disease. This offers opportunities for the development of new drugs. They have published their findings in the journal BMC Psychiatry.https://www.gesundheitsindustrie-bw.de/en/article/press-release/schizophrenia-nmi-observes-processes-nerve-cells
Press release - 11/12/2024 Top German research prize goes to Freiburg cancer researcher The Gottfried Wilhelm Leibniz-Prize 2025 goes to Prof. Dr Robert Zeiser for his outstanding research in haematology and immunology. Zeiser’s research at the University of Freiburg and the Medical Center – University of Freiburg have led, among other things, to new types of cancer therapy that has increased survival rates and the patients’ quality of life.https://www.gesundheitsindustrie-bw.de/en/article/press-release/top-german-research-prize-goes-freiburg-cancer-researcher
Press release - 09/12/2024 Brain tumour cells rapidly integrate into brain-wide neuronal circuits Researchers at the Medical Faculty of Heidelberg University and the Heidelberg University Hospital have used modified rabies viruses to label glioblastoma tumour cells and their direct cell contacts in the mouse brain. The new method showed that the tumour cells are connected to different types of nerve cells throughout the entire brain at a very early stage of the disease. https://www.gesundheitsindustrie-bw.de/en/article/press-release/brain-tumour-cells-rapidly-integrate-brain-wide-neuronal-circuits
NMI spin-off develops theranostics - 02/12/2024 immuneAdvice develops diagnostics to predict the efficacy of immunotherapies Certain types of cancer are already being effectively treated using immunotherapies, though success rates can vary significantly between patients. Researchers from the Natural and Medical Sciences Institute (NMI) in Reutlingen, along with colleagues at the University of Tübingen, are working on a diagnostic approach to accompany therapy, which would rapidly assess whether the treatment is effective or requires adjustment. https://www.gesundheitsindustrie-bw.de/en/article/news/immuneadvice-develops-diagnostics-predict-efficacy-immunotherapies
Vicinity Bio: Optimisation of cancer diagnostics - 27/11/2024 Comprehensive histological diagnostics through high-dimensional imaging and artificial intelligence Microscopic examination of tissue samples is essential, particularly in tumour diagnostics. The Tübingen-based company Vicinity Bio leverages cutting-edge imaging technologies combined with machine learning to generate comprehensive datasets of individual cells from tissue sections. This approach not only helps identify more targeted therapies but also enhances our understanding of cellular functions and processes within tissues and tumours.https://www.gesundheitsindustrie-bw.de/en/article/news/Comprehensive-histological-diagnostics-through-high-dimensional-imaging-and-artificial-intelligence
Press release - 26/11/2024 Cellular “power plants” control inflammation Researchers at the Medical Center – University of Freiburg and the University’s CIBSS Cluster of Excellence discover how mitochondria not only produce energy but also influence inflammation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cellular-power-plants-control-inflammation
Press release - 26/11/2024 Collaborative research centres on kidney and brain prolonged On 25 November, the German Research Foundation (DFG) announced the continued funding of two existing Collaborative Research Centres (CRC) at the University of Freiburg’s Faculty of Medicine. In CRC 1453 Nephrogenetics (NephGen), doctors and researchers are using genetic information to search for mechanisms underlying kidney diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/collaborative-research-centres-kidney-and-brain-prolonged
Press release - 25/11/2024 Chromosomal chaos promotes therapy resistance in leukemia cells and opens up new treatment approaches Chromosomal instability plays a role in the progression of cancer: it shapes the properties of tumor cells and drives the development of therapy resistance. Scientists from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM* and the European Molecular Biology Laboratory (EMBL) used state-of-the-art single-cell analysis methods to analyze the cellular heterogeneity of a specific form of acute myeloid leukemia. https://www.gesundheitsindustrie-bw.de/en/article/press-release/chromosomal-chaos-promotes-therapy-resistance-leukemia-cells-and-opens-new-treatment-approaches
Press release - 20/11/2024 New bioengineering approaches for the automated production of complex organoids The reproducible and precise production of complex organoid models to simulate human organ malfunctions is the focus of an interdisciplinary research project at Heidelberg University. A research team from the life and engineering sciences is looking to combine the engineering of molecular systems with machine learning and automated production methods. https://www.gesundheitsindustrie-bw.de/en/article/press-release/neue-ansaetze-des-bio-engineering-fuer-die-automatisierte-herstellung-komplexer-organoide
Press release - 15/11/2024 Selenium proteins as a possible new target for cancer research An important enzyme helps the body produce selenium proteins – this discovery could open up new strategies for treating cancer in children. This has been published by scientists from the University of Würzburg, the University Sao Paolo, the German Cancer Research Center (DKFZ) and the Heidelberg Stem Cell Institute HI-STEM*.https://www.gesundheitsindustrie-bw.de/en/article/press-release/selenium-proteins-possible-new-target-cancer-research
Press release - 14/11/2024 Novel method for fighting tumors Making existing cancer therapy more efficient while significantly reducing the side effects on healthy tissue - this is the aim of a project at Aalen University. It is being funded with one million euros from the Carl Zeiss Foundation. The biophysicist and his team are developing innovative nanoparticles made of gold. The particles use radiotherapy and chemotherapy simultaneously and kill the cancer cells in a targeted manner.https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-method-for-fighting-tumors
Advancing quantum technology into real-world applications - 06/11/2024 QSens: BMBF future cluster brings quantum sensors of the future into medicine The BMBF-funded future cluster ‘QSens – Quantum Sensors of the Future’ is developing ultra-sensitive sensors that could open up new options in medicine, enabling faster drug research, more accurate diagnostics and improved rehabilitation. The universities of Stuttgart and Ulm are actively working with 17 industry partners to put these cutting-edge innovations to immediate practical use.https://www.gesundheitsindustrie-bw.de/en/article/news/qsens-bmbf-future-cluster-brings-quantum-sensors-future-medicine
Press release - 05/11/2024 How biomedical innovation improves preclinical research 3D tumor models, simulations of drug responses or plant stems used for testing heart stents: the 3R-BioMedicUS center at the University of Stuttgart is developing innovative biomedical approaches to improve preclinical studies, to be seen in the new video.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-biomedical-innovation-improves-preclinical-research
Press release - 09/10/2024 Language model "UroBot“ surpasses the accuracy of experienced urologists Scientists at the German Cancer Research Center (DKFZ), together with doctors from the Urological Clinic of the Mannheim University Hospital, have developed and successfully tested a chatbot based on artificial intelligence. "UroBot" was able to answer questions from the urology specialist examination with a high degree of accuracy, surpassing both other language models and the accuracy of experienced urologists. https://www.gesundheitsindustrie-bw.de/en/article/press-release/language-model-urobot-surpasses-accuracy-experienced-urologists
Press release - 25/09/2024 How do rare genetic variants affect health? AI provides more accurate predictions Whether we are predisposed to particular diseases depends to a large extent on the countless variants in our genome. However in the case of genetic variants the influence on the presentation of certain pathological traits has been difficult to determine. Researchers have introduced an algorithm based on deep learning that can predict the effects of rare genetic variants. https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-do-rare-genetic-variants-affect-health-ai-provides-more-accurate-predictions
Chronic inflammatory bowel diseases - 25/09/2024 Proinflammatory regulatory T lymphocytes as a therapeutic target in Crohn's disease Chronic inflammatory bowel diseases are very stressful for those affected and increase the risk of bowel cancer. PD Dr. Robyn Laura Kosinsky from the Bosch Health Campus in Stuttgart, together with researchers from the USA, identified disfunctional regulatory T cells as important drivers of inflammation in Crohn's disease. They also found that with the help of an epigenetically active drug, it was possible to restore the cells’ original…https://www.gesundheitsindustrie-bw.de/en/article/news/proinflammatory-regulatory-t-lymphocytes-therapeutic-target-crohns-disease
Press release - 25/09/2024 How developmental signals can contribute to Genomic Mosaicism Certain developmental signals play a significant role in maintaining our genetic blueprints. They prevent alterations in the genome, known as mosaicism. The underlying biological mechanism helps the DNA to produce an identical copy of itself during cell division using the original genetic blueprint. However, it can also contribute to genomic mosaicism during nerve cell development.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-developmental-signals-can-contribute-genomic-mosaicism
Press release - 19/09/2024 Quality standards for looking into the tumor genome Personalized medicine with individually tailored therapies is becoming more a reality in cancer. This requires a look into the genetic material of tumors, a molecular diagnostic tumor profile. A research group from the German Network for Personalized Medicine (DNPM) has recorded the quality standards according to which genome analyses are carried out in Germany. The data is a prerequisite for integrating gene sequencing into routine care. https://www.gesundheitsindustrie-bw.de/en/article/press-release/quality-standards-looking-tumor-genome
Press release - 26/08/2024 Synthetic Immunology: Approaching a Turning Point in the Treatment and Prevention of Disease Synthetic immunology is the topic of an article in the “Perspectives” section of the journal “Nature Nanotechnology”. Herein, Heidelberg researchers describe a so-called bottom-up approach that uses the toolbox of nanotechnology and synthetic biology to construct systems from molecular building blocks and specifically equip them with immune functions. https://www.gesundheitsindustrie-bw.de/en/article/press-release/synthetic-immunology-approaching-turning-point-treatment-and-prevention-disease
Press release - 22/08/2024 Validated targets for personalized cancer immunotherapy Knowledge of the target structures for the immune cells is a basic prerequisite for the development of personalized cancer immunotherapies. Scientists from the German Cancer Research Center and the NCT Heidelberg are publishing a sensitive method based on mass spectroscopy to identify such tumor-specific "neoepitopes". The analytical method is designed to detect these low abundance protein fragments and requires minimal amounts of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/validated-targets-personalized-cancer-immunotherapy
Press release - 21/08/2024 A molecular control hub maintains order How are proteins in our cells modified while they are still being synthesized? An international team of researchers from the University of Konstanz, Caltech, and ETH Zurich has deciphered the molecular mechanism of this vital process. https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-control-hub-maintains-order
Press release - 14/08/2024 New vaccine against cervical cancer combines prophylactic and therapeutic activities Scientists at the German Cancer Research Center (DKFZ) have developed a completely new vaccination concept. The vaccine is inexpensive and protects mice against almost all cancer-causing HPV types. In addition to preventing new infections, the vaccine also triggers cellular immune responses against HPV-infected cells and may therefore also have a therapeutic effect against existing infections.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-vaccine-against-cervical-cancer-combines-prophylactic-and-therapeutic-activities
Press release - 01/08/2024 Targeted therapy for cancer of unknown primary (Cup) Encouraging results from a large international study led by Heidelberg have recently been published in the journal “Lancet”: The genetic material of cancer cells with unknown tissue of origin contains numerous targets for specific drugs that are already available and have been developed to treat other forms of cancer. These suppressed the disease in CUP patients for significantly longer than chemotherapy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeted-therapy-cancer-unknown-primary-cup
Press release - 11/07/2024 Presentation of the DKFZ Innovation Award and DKFZ Patient Expert Award The "Friends of the German Cancer Research Center" association supports the DKFZ and aims to help strengthen its position in international competition. With the DKFZ Innovation Award presented at this year's DKFZ annual reception, the association honored Titus Brinker as a researcher whose highly innovative work builds a bridge from research to practical application with commercialization potential.https://www.gesundheitsindustrie-bw.de/en/article/press-release/presentation-dkfz-innovation-award-and-dkfz-patient-expert-award
Press release - 10/07/2024 HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.https://www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-raises-euro-15-million-series-c-round-advance-clinical-development-hrx-215-liver-regeneration
TWYCE GmbH - 10/07/2024 Better immune response against prostate cancer thanks to new bispecific antibodies TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/better-immune-response-against-prostate-cancer-thanks-new-bispecific-antibodies
Press release - 09/07/2024 Unique characteristics of previously unexplored protein discovered Freiburg-Prague research collaboration achieves scientific breakthrough in understanding cell division. The international research collaboration has uncovered a new mechanism of the crosstalk between microtubules and actin cytoskeleton during cell division and revealed unique characteristics of the previously unexplored protein FAM110A.https://www.gesundheitsindustrie-bw.de/en/article/press-release/unique-characteristics-previously-unexplored-protein-discovered
Press release - 05/07/2024 Outstanding ideas – new imaging processes for cancer diagnostics and nanopropellers for ocular gene therapy The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.https://www.gesundheitsindustrie-bw.de/en/article/press-release/outstanding-ideas-new-imaging-processes-cancer-diagnostics-and-nanopropellers-ocular-gene-therapy
Press release - 05/07/2024 The Symphony of Organelles With "OrgaPlexing", scientists at the MPI of Immunobiology and Epigenetics have developed a new method that shows how guardian cells of the immune system, the macrophages, orchestrate their cell structures during inflammation or bacterial infection, making it possible to observe the interactions between several organelles simultaneously and thus providing insights into cell metabolism and the production of inflammatory molecules. https://www.gesundheitsindustrie-bw.de/en/article/press-release/symphony-organelles
Press release - 04/07/2024 Antibody can improve immune cell therapy against leukemia Scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have shown that the combination of therapeutic immune cells, known as CAR T cells, and a bispecific antibody could improve the treatment of leukaemia. In the culture dish and in mice, they tested CAR-T cells directed against the B-cell marker CD19 in combination with bispecific antibodies that bind to the B-cell-specific protein CD20. https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibody-can-improve-immune-cell-therapy-against-leukemia
Press release - 03/07/2024 Max Planck scientists develop cost-efficient medical imaging method Max Planck scientists will present a low-field magnetic resonance imaging (MRI) scanner in Lindau. Two researchers from the MPI for Biological Cybernetics in Tübingen, Germany, will present a model of a new low-field MRI system. It combines hyperpolarization with imaging techniques that can be run at low magnetic field strengths. The quality of the MRI images can be enhanced with the help of artificial intelligence.https://www.gesundheitsindustrie-bw.de/en/article/press-release/max-planck-scientists-develop-cost-efficient-medical-imaging-method
Press release - 03/07/2024 CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-initiates-strategic-restructuring-align-resources-focus-high-value-mrna-pipeline-opportunities
Press release - 02/07/2024 DKFZ spin-off Epignostix raises €4.3m seed round to commercialize diagnostic tumor classifier Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces €4.3M in seed funding. This investment will enable Heidelberg Epignostix to make a substantial leap forward in driving market development for its flagship indication for brain tumor classification.https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-spin-epignostix-raises-euro-43m-seed-round-commercialize-diagnostic-tumor-classifier
Press release - 17/06/2024 DNA as building material for tiny machines and artificial cells Humboldt Research Award winner Prof. Hao Yan has been conducting research at the 2nd Institute of Physics at the University of Stuttgart since May. He is regarded as one of the world's leading experts in the field of DNA nanotechnology. "My work has many points of commonality with the topics that my colleagues in Stuttgart are focusing on," says Yan. "I have therefore been cooperating with Professor Laura Na Liu's working…https://www.gesundheitsindustrie-bw.de/en/article/press-release/dna-building-material-tiny-machines-and-artificial-cells
Press release - 13/06/2024 Which of the two DNA strands is damaged influences the cell's mutation profile Cancer genomes are the result of diverse mutation processes. Scientists have analyzed the molecular evolution of tumors after exposure to mutagenic chemicals. DNA lesions that persists unrepaired over several cell generations lead to sequence variations at the site of damage. This enabled the researchers to distinguish the contribution of the triggering lesion from that of the subsequent repair in shaping the mutation pattern.https://www.gesundheitsindustrie-bw.de/en/article/press-release/which-two-dna-strands-damaged-influences-cells-mutation-profile
Press release - 13/06/2024 Position of the cell nucleus affects epigenetics and therefore gene activity and cell function Depending on whether the cell nucleus of an epithelial cell is located on the outer or inner side of the tissue, the genome is more or less acetylated - genes can therefore be translated easier or harder. Scientists from the German Cancer Research Center (DKFZ) have demonstrated this for the first time in the development of the Drosophila wing. https://www.gesundheitsindustrie-bw.de/en/article/press-release/position-cell-nucleus-affects-epigenetics-and-therefore-gene-activity-and-cell-function
Press release - 31/05/2024 Toolkit makes protein design faster and more accessible The Damietta Server broadens the accessibility to protein design research and its applications in various biotechnological and biomedical fields. Researchers at the Max Planck Institute for Biology Tübingen, the University of Tübingen, and the University Hospital Tübingen have developed a web-based toolkit to accelerate and simplify protein design without needing powerful computers or extensive protein design expertise on the user’s end.https://www.gesundheitsindustrie-bw.de/en/article/press-release/toolkit-makes-protein-design-faster-and-more-accessible
Press release - 31/05/2024 Heidelberg University successful with six bids for collaborative research In the current approval round of the German Research Foundation (DFG) Heidelberg University has been successful with six applications for grants to fund major, internationally visible research consortia. The six research consortia − three of them will reach the maximum funding length of twelve years after their extension − are to receive financial resources totalling nearly 87 million euros over a period of four years.https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-university-successful-six-bids-collaborative-research
Press release - 24/05/2024 Research Training Group on Cancer Surgery: German Research Foundation approves second funding period Since 2019, the Research Training Group (RTG) "Intraoperative Multisensoric Tissue Differentiation in Oncology," a collaboration between the University of Stuttgart and the University of Tübingen, has been advancing research in medical technology. With the help of new sensor methods, the researchers want to help make surgical procedures on cancer patients safer and more effective.https://www.gesundheitsindustrie-bw.de/en/article/press-release/research-training-group-cancer-surgery-german-research-foundation-approves-second-funding-period
Press release - 23/05/2024 Predicting cancer risks on the basis of national health data Scientists from the German Cancer Research Center (DKFZ) and the European Bioinformatics Institute EMBL-EBI, Hinxton, UK, are using the Danish health registers to predict individual risks for 20 different types of cancer with a high degree of accuracy. The prediction model can also be transferred to other healthcare systems. https://www.gesundheitsindustrie-bw.de/en/article/press-release/predicting-cancer-risks-basis-national-health-data
Press release - 16/05/2024 Colorectal cancer: tracking down subtypes Colorectal cancer differs from patient to patient. That is why scientists are looking for characteristic tumors markers that allow to make predictions about the likely response to certain therapies and the individual prognosis. The aim is to identify colorectal cancer subtypes so that these can then be treated in a customized manner. https://www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-tracking-down-subtypes
Press release - 15/05/2024 Tumour tissue on a chip: new possibilities for cell therapies and personalized medicine How do tumors react to a certain therapeutic approach? Knowing this before the start of a therapy would be of enormous value for people suffering from cancer as well as for the doctors treating them. Researchers have now made this very observation possible for the CAR-T cell therapy. This allows us to individually investigate how exactly these tumor cells react to the planned therapy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tumour-tissue-chip-new-possibilities-cell-therapies-and-personalized-medicine